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This report supplements the only report that we know of that relates clozapine-induced stuttering to epileptic brain activity (3) . An association between stuttering and dystonia has been previously described (1), but our patient showed no evidence of dystonia, which was thus excluded as a cause of stuttering. The authors of that report (1) may have misattributed stuttering to coincidental dystonia, although their patient had significant EEG abnormalities.
Stuttering has been demonstrated to occur in association with seizures and to respond to treatment with antiepileptic drugs (4) . Patients with stuttering without seizures have also been shown to have EEG abnormalities, such as background activity that is too slow for age (5) . When coupling this observation with the hypothesis that patients with stuttering may have predominantly left-sided abnormality (6) , it is tempting to speculate, albeit with caution, that stuttering accompanied by EEG abnormalities-especially left-sided slowing (as in this case)-in patients taking clozapine may be a harbinger of seizures. Further studies are required to address this issue.
Transcranial Magnetic Stimulation for Panic
TO THE EDITOR: Studies have suggested that fast repetitive transcranial magnetic stimulation (rTMS) of the left dorsolateral prefrontal cortex is a promising treatment strategy for major depression (1) . Moreover, slow rTMS of the right dorsolateral prefrontal cortex has been also shown to improve symptoms of depression and posttraumatic stress disorder (2) . However, studies of its anxiolytic properties are hampered by the complex symptom profile of the anxiety disorders. Thus, the investigation of rTMS in a specific paradigm of experimentally induced anxiety theoretically may be a promising avenue for testing whether rTMS exerts specific anxiolytic effects.
The administration of cholecystokinin tetrapeptide (CCK-4) provokes panic-like symptoms both in healthy volunteers and in patients with panic disorder that can be blocked by use of antipanic agents, such as benzodiazepines and antidepressants (3) , and may therefore serve to test the anxiolytic properties of new therapeutic strategies. We report on a patient treated with right prefrontal rTMS who showed a reduction in panic disorder symptoms and improvement in CCK-4-induced panic attacks, associated with blunting of the CCK-4-induced elevation of ACTH and cortisol.
Ms. A, a 52-year-old woman, had been suffering from panic disorder (according to DSM-IV criteria) with six panic attacks per week for 13 months. She had not received any prior treatment and was medication free at the time of admission. Ms. A gave her informed consent for treatment after the procedure had fully been explained to her; she was treated in a pilot investigation with slow rTMS of the right dorsolateral prefrontal cortex for 2 weeks (10 sessions, 1200 stimuli/day, 1 Hz, 110% intensity, which was related to individual motor threshold). At baseline and after rTMS treatment, a CCK-4 challenge was performed to assess the putative effects of rTMS in its ability to induce panic attacks. Panic symptoms were assessed by applying the Acute Panic Inventory (4) and the Panic Symptom Scale (5). Cortisol and ACTH plasma levels were determined during the challenge. Ratings for general anxiety LETTERS TO THE EDITOR and naturally occurring panic attacks were assigned after use of the Hamilton Anxiety Rating Scale and Bandelow's Panic and Agoraphobia Scale (6).
After 2 weeks of rTMS, Ms. A reported a marked improvement in her anxiety. Her score on the Hamilton anxiety scale had decreased from 27 to 6 (-78%), and her score on the Panic and Agoraphobia Scale had decreased from 34 to 14 (-59%). Moreover, a marked reduction in her CCK-4-associated panic symptoms was observed after the second challenge. Her maximum scores on the Acute Panic Inventory and the Panic Symptom Scale decreased from 34 to 20 (-41%) and from 38 to 26 (-32%), respectively. Her maximum serum cortisol level CCK-4 challenge decreased from 884 nmol/liter to 0 nmol/liter; her maximum serum ACTH level decreased from 1.47 pmol/liter to 0.35 pmol/liter. At her 4-week follow-up examination, Ms. A's condition was stable, so she did not require further pharmacotherapy.
This report adds to previous evidence that slow rTMS of the right prefrontal cortex ameliorates the symptoms of major depression and anxiety disorders (1) . In contrast, single instances of panic disorder and generalized anxiety disorder have been reported in which panic and anxiety increased after fast rTMS over left or right prefrontal sites (7) . However, slow rTMS is hypothesized to be associated with the opposite effect on cortical excitability-namely, putative inhibitory net effects-in contrast to the augmentative effects of fast rTMS (8) .
The clinical findings in the present case report are strengthened by the observation of a complete blunting of CCK-4-induced serum cortisol increase after rTMS, despite the occurrence of mild symptoms of anxiety. This is compatible with the putative effect of rTMS on hypothalamic-pituitary-adrenal reactivity to CCK-4 administration. However, in view of the high susceptibility of patients with panic disorder to placebo effects, we must consider the possibility that placebo effects may also have influenced our findings. Future studies should investigate the anxiolytic potential of rTMS in patients with panic disorder under placebo-controlled conditions. Nortriptyline for Depression and Vulvodynia TO THE EDITOR: There is an intimate and complex relationship between depression and pain, and patients suffering from depression are at a greater risk for developing various chronic pain syndromes than individuals without depression (1). Vulvodynia, a neuropathic pain syndrome that affects the vulva and external genitalia, is often associated with depression (2, 3) . It has been suggested that the condition may respond favorably to antidepressant treatment (2), but to date we are aware of no specific case reports, much less controlled studies, on the topic. We recently cared for a patient with major depression and vulvodynia who responded dramatically to treatment with a tricyclic antidepressant. To our knowledge, there has been only a single positive open trial of antidepressants for chronic pelvic pain (4), but vulvodynia is felt to be a distinct syndrome (3) . Its dysesthetic character, lack of associated tissue pathology, and strong association with depression are reminiscent of other neuropathic syndromes, such as facial neuralgia and glossodynia. Our patient responded dramatically to treatment with a tricyclic antidepressant but not to a variety of other agents. (Spontaneous remission is a possibility but seems unlikely after 2 years of unremitting symptoms.) It is unclear whether this LETTERS TO THE EDITOR was because of her better response to nortriptyline or to the inherent superior efficacy of tricyclics in the treatment of neuropathic pain (5) . Further studies will be necessary to establish the efficacy of antidepressants in general, and tricyclics in particular, in the treatment of vulvodynia. Bay Pines, Fla.
Clozapine for First-Episode Schizophrenia
TO THE EDITOR: The use of clozapine to treat first episodes of psychosis has rarely been reported (1, 2) . We present the case of a young man with a first episode of schizophrenia who had a sustained, complete resolution of symptoms with clozapine treatment.
Mr. A was a 30-year-old man who came to the emergency room after attempting suicide by overdose. In the preceding 6 months, he had noticed feelings of being watched and feared a Mafia plot against him. He had delusions of reference about the television and thought that strangers knew his history. He claimed to have telepathy, thought that energy was passing between people, and heard voices telling him to kill himself. The emergency room physician proposed a diagnosis of paranoid schizophrenia, which was confirmed when measured against DSM-IV criteria upon his first hospital admission by a physician experienced in schizophrenia research.
Six months earlier, Mr. A had been treated for depressive symptoms by a general practitioner, who prescribed an 8-week trial of paroxetine. Mr. A's family history had revealed alcoholism, depression, bipolar affective disorder, and suicide by an uncle. Mr. A reported drinking two to three beers per week and occasionally using cannabis. When Mr. A was admitted for treatment of his first episode of psychosis, he initially had a short (2-week) trial of olanzapine. While he was still experiencing his first episode of psychotic illness, he consented to participate in the International Suicide Prevention Trial (InterSePT) and was given clozapine during a 4-week crossover period in which he received both antipsychotics. Clozapine, 12.5 mg/day, was gradually increased over 5 weeks to 100 mg/ day and was maintained at a dose of 112.5 mg/day. Concomitant medication included only gabapentin, 2400 mg/ day, for situational anxiety (3).
Mr. A's baseline scores were rated with the Positive and Negative Syndrome Scale (4) (positive symptoms: score= 19, negative symptoms: score=20, total score=90), the Clinical Global Impression (CGI) scale (score=4), the Calgary Depression Scale (5) (depression: score=15, anxiety: score=5), the InterSePT Suicidality Scale (6) (score=9), and the Extrapyramidal Symptom Rating Scale (7) (parkinsonism: score=7, dyskinesia: score=1). After 8 weeks of treatment he had improved dramatically. He maintained this improvement, and after 2 years his total score on the Positive and Negative Syndrome Scale was 30 (minimal score=30), his CGI scale score was 1, his scores on the Calgary Depression Scale were 0 for both depression and anxiety, his InterSePT Suicidality Scale score was 0, and his score on the Extrapyramidal Symptom Rating Scale showed no movement disorder. After 2½ years of clozapine treatment, he lives with a roommate and works fulltime in the aviation industry.
Several authors have questioned whether clozapine should be indicated as a first-line treatment for early psychosis (1, 2, 8) . The risk-benefit ratio has been reappraised (9) in view of the lower rates of relapse, hospitalization, extrapyramidal symptoms, and suicidality and the improvements in negative symptoms, cognition, and social functioning associated with clozapine. Long-term outcome studies of patients treated with clozapine early in the course of their illness and spared the neurotoxicity of long-term exposure to traditional antipsychotics are needed.
Mania in Hyperandrogenism, Insulin Resistance, and Nigricans Acanthosis Syndrome
TO THE EDITOR: Hyperandrogenism, insulin resistance, and acanthosis nigricans (HAIR-AN) syndrome has been defined only in the past 20 years and may be present in as many as 1%-3% of all women with hyperandrogenism (1). A case of organic mood disorder (depressed type) associated with the HAIR-AN syndrome, which improved markedly in response to ovarian suppression with oral contraceptives, has been documented (2) . In this report, we describe a patient with HAIR-AN syndrome who developed her first manic episode after she had stopped taking her birth control pills 2 months earlier.
Ms. A, a 19-year-old Hispanic woman with no prior psychiatric diagnosis, was brought to the emergency department by police during a manic episode. When she arrived at the medical center, her symptoms were characterized by an elevated mood, a lessened need for sleep, racing thoughts, and pressured speech. She also exhibited grandiose delusions, believing that she was the messenger of God and that she was so rich that she could buy 50 cars for the poor. At further questioning, Ms. A indicated that she had run away from home a week before admission, after a disagreement with her stepfather.
Her past medical history revealed a history of hirsutism and a diagnosis of polycystic ovary disease. Ms. A had been treated with oral contraceptives for about 6 months. She had stopped taking the birth control pills 2 months before the current episode. Although Ms. A reported a history of marijuana and cocaine abuse, her urine and serum toxicology screens at admission were negative for any substance. The results of other routine laboratory tests, including a CBC and measurements of glucose, blood urea nitrogen, creatinine, potassium, sodium, chloride, bicarbonate, and thyroid-stimulating hormone, were within normal limits.
Ms. A's physical examination was significant for a male pattern of hair growth on her face and hyperpigmented skin on the nape of her neck. The results of subsequent endocrinological tests were consistent with the diagnosis of HAIR-AN syndrome: an elevated insulin level of 54.7 µU/ml (normal range=0-25 µU/ml), an elevated testosterone level of 0.93 ng/ml (normal range=0.14-0.76 ng/ml), a normal level of follicle-stimulating hormone (3.2 mIU/ml), and a normal level of luteinizing hormone (8.10 mIU/ml). The results of imaging studies, including magnetic resonance imaging of the head and an abdominal computerized tomography scan, were unremarkable and were not suggestive of growth in the pituitary or adrenal glands.
While she was in the hospital, Ms. A's manic symptoms were successfully treated with a combination of lithium, divalproex sodium, and quetiapine. She refused to take oral contraceptives, despite the possible association of her mood symptoms with the discontinuation of birth control pills. After 2 weeks of hospitalization, she returned home with her parents.
The primary abnormality seen in patients with the HAIR-AN syndrome is believed to be insulin resistance with compensatory higher circulating insulin levels (1). Chronic elevated insulin is hypothesized to stimulate receptors for ovarian and epidermal insulin-like growth factors, resulting in hyperandrogenemia and hyperpigmentation, respectively (1, 3). Levin et al. (2) described a case of organic mood disorder (depressed type) in association with the HAIR-AN syndrome and noted that the patient's depressive symptoms improved with the initiation of oral contraceptives. However, no reported cases of mania associated with HAIR-AN syndrome have been described, to our knowledge. This report may represent the first documented case of mania in a patient with HAIR-AN syndrome; of more interest, the patient's manic symptoms emerged 2 months after she stopped treatment with oral contraceptives. However, we cannot overlook the possibility that our patient's manic episode was coincidental (in the context of HAIR-AN syndrome and the cessation of treatment with oral contraceptives) but find the association noteworthy and in need of further study.
Suicide Attempt After Use of Herbal Diet Pill
TO THE EDITOR: Ma-huang, or ephedra, an extract of the plant species Ephedra sinica, grows mainly in Mongolia near the Chinese border. Its main compounds are alkaloids of the 2-aminophenylpropane type, l-ephedrine and d-pseudoephedrine (1), and it is found in many over-the-counter weightloss aids. There have been reports (2-5) of significant adverse health consequences associated with its use. We report a case of suicide attempt and organically induced mood disorder associated with use of a diet pill containing Ma-huang.
Ms. A, a 32-year-old mother of two children, was brought to the hospital in a comatose state after she had swallowed 80 tablets of acetaminophen, 60 tablets of an herbal weight-loss supplement, and an unknown number of multivitamin tablets. She had no past history of mood disorders, according to both herself and her husband. She had started using the herbal weight-loss supplement about 2 months before her hospitalization. She reported that since that time, she had been feeling depressed most of the time, had been irritable, and had poor impulse control at work and at home. She had yelled at her boss and at her husband and daughter and had thrown things at them during moments of rage. She also reported frequent suicidal ideation and feelings of guilt. She had more energy and slept less-no more than 3 hours a night. She also heard voices calling her name.
After the overdose, Ms. A was admitted into the intensive care unit, where supportive measures were administered. Her serum acetaminophen level was 182.31 µg/ml at admission and decreased to <1.00 µg/ml 2 days later. The product label for the herbal weight-loss supplement that the patient took states that a two-tablet serving contains 324 mg of Ma-huang extract, standardized for 20 mg of ephedrine alkaloids. The recommended dose is two tablets per day. Our patient said that she had been taking four tablets per day for 2 months. There are many reports in the literature about the adverse effects of Ma-huang, including mania (2, 6), psychosis (4), hypertension (3), tachycardia (3), and myocardial infarction. Many deaths reported to the Food and Drug Administration (FDA) have been attributed to this herbal substance (4). The users of products containing Ma-huang are increasing in number, owing in large part to the fact that it is an herbal, or "natural," drug and thus is perceived as being safe. Some individuals exceed the recommended dose when they are self-medicating, and this can contribute further to adverse effects. Unfortunately, there are not enough studies of the safety and efficacy of this herb. Until we establish some kind of reporting system that allows the FDA to keep track of adverse reactions to Ma-huang, there will be many unidentified adverse events. That makes questioning patients regarding the use of over-the-counter remedies essential.
Use of Dreams by Psychopharmacologists
TO THE EDITOR: In a recent issue, Morton F. Reiser, M.D. (1), brought together sources from psychoanalysis and neuroscience to evaluate the role of the dream in current psychiatric thinking. I would like to add a contribution from psychopharmacology to the subject. Since the dream records first and foremost the current affect of the patient, it can-and, I believe, should-be used in the psychopharmacologic treatment of mental illness. Whether or not the dream is "the royal road to the unconscious"-and I believe it is-it is certainly the royal road to the affect. In my experience, the initial affect of the dream or sequence of dreams corresponds to the affect with which the patient awakens. I believe that the ultimate target symptom to be addressed in psychopharmacology is the patient's affect, and it is for this reason that the dream provides a quick and efficient source of information-or, rather, supplementation to other clinical data-for the purpose of deciding which medication to prescribe and how to modify the dose. A description of a recent patient illustrates this concept.
Mr. A was a 24-year-old man with severe anorexia nervosa who had no improvement after 10 hospitalizations in programs for the treatment of eating disorders and the efforts of a number of psychopharmacologists. He had had many types of pharmacologic intervention, and when I first saw him, he was taking 40 mg/day of fluoxetine because his anorexia nervosa was complicated by severe obsessive-compulsive neurosis. However, I saw no depressive affect in Mr. A. On the contrary, the most recent dream he could recall was that he was in bed with a "very pretty girl." That did not sound like a depressive dream to me but, rather, a dream that indicated a euphoric mood. His appearance at consultation was also euphoric. There was no sexual activity in the dream; he had never experienced any sexual contact with a partner. However, he was very close to his mother, who was very sympathetic and indulgent, in contrast to his father, who was harsh and critical.
I reasoned that the anorexia nervosa might have been a self-destructive effort to counteract his "up" mood in the same way that self-defeating behavior on the part of patients with mania can be seen as a corrective attempt and often interpreted as punishment. Accordingly, I prescribed olanzapine, 10 mg/day, primarily as a depressive drug, although I was obviously taking advantage of its propensity for increasing Mr. A's appetite. Within 3 days, for the first time in years, Mr. A began eating eagerly and with appetite. I gradually increased his dose of olanzapine to 20 mg/day, wondering whether I might not be pressing too hard. However, Mr. A came in delighted with his change in status and reported his weight gain to me daily.
We had been discussing Mr. A's difficulty in finding appropriate women to date. One day he reported having a dream in which he was with two girls who told him that they heard him "farting," that he was "shitty," and that "they would not have anything to do" with him. He started to weep as he described the dream. Clearly, this was a change in affect and indicated a switch in mood to the depressive side, which I had anticipated. I reduced his dose of olanzapine to 15 mg/day and added 15/mg day of mirtazapine. He then recovered completely.
Thus, the dream can be used advantageously by psychopharmacologists. However, from a theoretical point of view, we may infer also that the dream primarily expresses affect directly and probably selects content from the store of memories associated with that affect. What Freud called "dream work" creates a story line of sorts that integrates the images and processes of the dream. It does not do nearly as well as waking consciousness does, but it does integrate the affects, images, and processes admitted to our waking consciousness.
Antistreptolysin-O Titers: Implications for Adult PANDAS
TO THE EDITOR: A diagnosis of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) is made when neuropsychiatric disease is precipitated by streptococcal infection (1). Antistreptolysin-O titers are an important tool for diagnosing recent streptococcal infection in patients with Sydenham's chorea and PANDAS, since throat cultures are usually negative because of the latent onset of the neuropsychiatric disease. The upper limit for normal antistreptolysin-O titers is 200 IU/ml in children, but no normal upper limit exists for healthy adults. We propose that an antistreptolysin-O titer of 270 IU/ml is the significant upper limit for healthy adults. This finding will aid in the investigation and diagnosis of new cases of adult PANDAS.
Because of recent reports of cases of PANDAS in adults (2, 3), we measured antistreptolysin-O titers for 50 healthy adults to determine a normal adult range and investigated the number of healthy adults with higher than normal antistreptolysin-O titers. Fifty healthy adults (25 men and 25 women) were recruited from the staff of a pediatric hospital between November 2000 and May 2001; they had a mean age of 35.6 years (range=19-57). Subjects were excluded if there was a history of neurological, psychiatric, or autoimmune disease. The time of their most recent sore throat was recorded; 30% of the subjects had had a sore throat within the 6 months before the blood sampling. Blood samples were processed within 1 day of receipt, and antistreptolysin-O titers were measured by using a standardized nephelometry technique.
The subjects' mean antistreptolysin-O titer was 122 IU/ml (range=50-376). Only 8% (four of 50) of the healthy adults had antistreptolysin-O titers higher than 200 IU/ml, 4% (two of 50) had titers over 300 IU/ml, and none had titers over 400 IU/ ml. According to the upper limit of 200 IU/ml for a normal pediatric antistreptolysin-O titer, 8% (four of 50) of the healthy adults had "abnormal" titers. In this healthy adult group, the upper limit (95th percentile) for a normal antistreptolysin-O titer was 270 IU/ml.
The patients with recent cases of adult PANDAS both had highly elevated antistreptolysin-O titers of 1600 IU/ml (2) and 739 IU/ml (3). We conclude that streptococcal serology is a useful diagnostic tool for assessing the etiology of new cases of neuropsychiatric disease in adults and propose an antistreptolysin-O titer of 270 IU/ml as the upper limit of normal for adults.
Pramipexole for Depression
TO THE EDITOR: Pramipexole is a dopamine agonist that is active primarily at the dopamine D 3 receptor but also at D 2 and to a lesser extent at D 4 . It was introduced for the treatment of idiopathic parkinsonism.
I noticed the use of pramipexole for the treatment of depression in a note in Psychiatry Drug Alerts. Initial reports suggested the use of pramipexole as an augmentation for current treatment with antidepressants-later and more hesitantly it was suggested as primary therapy. I am aware of no systematic large-scale studies of pramipexole as a treatment for depression.
My small group included 22 patients, 11 of each gender, who were treated in the course of psychoanalytic psychotherapy. They ranged in age from 20 to 60 years. They received treatment from less than 1 month to more than 6 months. In eight instances, pramipexole was combined with other antidepressant medications. Twenty of these patients had depression with another diagnosis on the manic-depressive spectrum, including borderline personality disorder. Two patients were severely inhibited, with profoundly low self-esteem. Eight experienced rapid cycling. The patients gave their oral assent to participate in the study.
After treatment with pramipexole, 13 of the 22 patients experienced complete or impressive alleviation of their depressive state; six were taking pramipexole alone, and seven had pramipexole added to their current antidepressant regimen, which had previously been ineffective. In five other patients, the illness was more complex and usually involved cyclingrapid or intermediate-accompanying borderline personality or bipolar disorder. Pramipexole contributed significantly to alleviation of the depressive component of the illness, but that was not enough to resolve the complex clinical picture of these five patients. One patient had to stop taking the drug at a dose of 3 mg/day because of unacceptable side effects; he received no therapeutic benefit at lower doses. Three patients could not tolerate the drug at all. In all, five patients could take no more than 0.5 mg/day or did well with less, four did well taking 0.5-1.0 mg/day, eight required 1-3 mg/day, and five required more than 3 mg/day. No patient took more than 4.5 mg/day.
The study group included three women who could tolerate no antidepressants; neither could they tolerate pramipexole. One complained of confusion, a second of sleepiness, and a third of "wired" and "spacey" sensations. For two of the women, even a small fraction of a tablet produced side effects. The other woman took no more than 0.5 mg t.i.d.
It was necessary in most cases to increase the dose over time as tolerance developed. However, tolerance did not develop any more quickly than with other antidepressants. Whenever a patient reached a maximum dose of 4.5 mg/day of pramipexole, if it was necessary to augment the dose, I added another antidepressant. In no case did pramipexole seem to become completely ineffectual. Side effects were rel-atively few and included nausea, sleepiness, and unremitting alertness, which for some patients led to a sleep deficit.
I infer from this study that pramipexole possesses significant antidepressant potency and is no less effective than any of the other antidepressants in use. It has relatively few side effects, has high patient acceptability, and is no more likely to require larger doses than any other antidepressant. I hesitate to prescribe it as a first-line treatment for depression because patients do not welcome having to take medication three times a day.
Recently, I have been prescribing ropinirole, which is similar to pramipexole except that it possesses some opioid characteristics. In the few months that I have been prescribing it, I find that patients prefer it to pramipexole and that it is more likely to raise self-esteem than pramipexole or conventional antidepressants. However, it seems to induce sleepiness as a side effect more often than does pramipexole.
Riverdale, N.Y.
Benzodiazepine Discontinuation in Generalized Anxiety Disorder
TO THE EDITOR: In an interesting study, Kark Rickels, M.D., et al.
(1) demonstrated the usefulness of imipramine in a benzodiazepine discontinuation program for patients with generalized anxiety disorder. Low anxiety scores (Hamilton Anxiety Rating Scale score: mean=12.5, SD=6.3) at baseline and at the 12-month follow-up and the fact that only 11 (21.2%) of 52 patients required pharmacotherapy (tricyclic antidepressants or selective serotonin reuptake inhibitors) to treat their anxiety symptoms makes one suspect that the majority of the subjects had either a mild form of generalized anxiety disorder or benzodiazepine dependence. This poses a limitation on the generalizability of the results. Maintenance therapy for generalized anxiety disorder is recommended for at least 1 year after control of anxiety symptoms has been achieved (2), and benzodiazepine dependence is known to occur at therapeutic doses (3). Dr. Rickels et al. considered the study group "rather treatment resistant" (1, p. 1978) on the basis of previous discontinuation attempts. However, these attempts were without any apparent therapeutic intervention. The use of nonpharmacological and pharmacological measures is an important factor in determining the success of benzodiazepine discontinuation (3). The dissatisfaction of the majority of the patients (75.7%) with benzodiazepine therapy for the management of anxiety may have been a motivating factor in these discontinuation attempts. Another argument against treatment resistance is the benzodiazepine-free status of 37.5% of the patients after 3 months of taking placebo alone.
We notice certain issues regarding the methods that might have had a bearing on the results of this study. It was not clarified in the article how the subjects were assigned to three study groups and whether random assignment was carried out to reduce rater or response bias. Moreover, the patients taking imipramine experienced side effects that could have compromised the study blind. The description of the 12-month follow-up assessment contains no mention of the differences among the three treatment groups regarding their benzodiazepine-free status. Logistic regression analysis showed that lower levels of baseline anxiety symptoms predicted a successful taper at 3 months. Baseline depressive symptoms were not analyzed, even though both anxiety and depressive symptoms were hypothesized to play an important part in benzodiazepine withdrawal (1). The 41.2% (seven of 17) of patients taking benzodiazepines at 3 months but not at 12 months might actually be lower, since the patients taking benzodiazepines at 3 months were more likely to drop out of follow-up by 12 months than the benzodiazepine-free patients (odds ratio=3.7).
Notwithstanding issues regarding conception and methods, this study opens up new avenues in tackling benzodiazepine dependence in long-term benzodiazepine users. ments made by Dr. Gutpa and colleagues, as they relate to the study group, the generalizability of the results, benzodiazepine dependence, long-term treatment for generalized anxiety disorder, resistance to benzodiazepine therapy, and the effect of treatment group on benzodiazepine status at 12 months, were adequately covered in the article. 
Early Onset of Schizophrenia
TO THE EDITOR: We read with great interest the article by Carole Di Maggio, M.D., and her colleagues (1) . Although the study presented some interesting data about decreasing age at onset of schizophrenia, it also raised some questions about the interpretation and analyses of the data. The authors presented retrospective data for medical records (N=877) from 1976, 1986, and 1996. Individuals in the study were divided into three birth cohorts: 1905-1944, 1945-1964, and 1965-1984 . However, the significant decrease in age at onset through time could be due to bias caused by the different age structures of the cohorts. Individual ages of the subjects in the 1905-1944 cohort were from 32 to 91 years, the subjects in the 1945-1964 cohort were aged 12 to 51 years, and the subjects in the 1965-1984 cohort were aged 1 to 31 years. Thus, all persons who died before the age of 32 could not be part of the 1905-1944 cohort. This might have been an important source of bias in the study because mortality is greater for patients with schizophrenia, but at the population level, the standardized mortality ratio for schizophrenia decreases exponentially with age (2). Only patients with illness onset before age 32 could be present in the youngest cohort. We calculated mean ages at onset on the basis of our data (3) for cohorts from 1950-1955 (N=4,023) and 1956-1961 (N= 2,941), with follow-up assessments made, respectively, at 1969-1978 and 1975-1984 . The mean ages at onset were 21.8 and 21.9 years. We suggest that the data presented by Dr. Di Maggio and colleagues should be reanalyzed with consideration of the different age structures.
Dr. Di Maggio and Colleagues Reply
TO THE EDITOR: We calculated mean ages for the cohorts in our study, taking into account their different age structures. For the third cohort (1965) (1966) (1967) (1968) (1969) (1970) (1971) (1972) (1973) (1974) (1975) (1976) (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) , the maximum age of the individuals was 29 (born in 1967 and hospitalized in 1996.)
In order to take this bias into account, we analyzed the data for only the patients with an onset before age 29 in the three cohorts. The cohort effect remained among the three groups, showing an increasingly lower age at onset of first psychotic symptoms from the first cohort A's lens changes were not representative of the most common forms of lens opacity, which are usually ascribed to lens toxins. Nor were they a type of lens opacity that is subject to reliable and consistent ascertainment. In fact, it has proven so difficult to evaluate minor lens opacities, such as the cortical vacuoles noted in Mr. A, that the most-accepted lens opacity classification system (Lens Opacities Classification System III) largely ignores them in favor of the more reliable ascertainment of cortical wedges and spokes (2) . Perhaps more important, the authors' assertion that Mr. A did not have any other risk factors is mistaken. Although their MEDLINE search "of articles on the patient's other medications revealed no association with cataracts" (1, p. 966), an abundant literature nevertheless exists on the association of agents used to treat schizophrenia and lens opacities. For instance, haloperidol, one of the agents used to treat Mr. A, has a recognized association with capsular cataracts after longterm therapy (3). Phenothiazines, also used to treat Mr. A, are recognized as causing deposits to form within the lens (4). Moreover, Isaac et al. (5) reported that the lens changes induced by phenothiazines are clearly deleterious. McCarty et al. (6) raised the suspicion that schizophrenia itself might be a risk factor for cataracts. Since poor nutrition is also a risk factor for cataracts (7) , it is difficult to tell whether lens opacity is a manifestation of the biology of schizophrenia or of poor eating habits.
Taken together, multiple and diverse risk factors existed for Mr. A's cataracts. That cataracts most often develop slowly and over long durations undermines any presumption of a specific attribution for the lens changes observed in Mr. A. With so many confounding variables, it impossible to determine a single cause of Mr. A's cataracts. Moreover, in my 3-year surveillance of ocular safety for AstraZeneca, which markets quetiapine, I have seen no clear signal emerge for toxicity in any part of the eye.
TO THE EDITOR: Michael J. Sernyak, M.D., et al. (1) reported that they found no evidence that clozapine reduces the rate of suicide and rejected the evidence from other authors that clozapine reduces the rates of suicide attempts and completions. Their arguments for rejecting the findings of the previous studies require careful scrutiny. Dr. Sernyak et al. claimed that there was no control group in the study by Meltzer and Okayli (2) , in which the rate of suicide attempts in the 2 years after clozapine treatment was initiated was 86% less than in the same patients in the 2 years before they began taking clozapine. Thus, each patient acted as his or her own comparison subject. Although this design is not as robust as a randomized, parallel-group, double-blind study, it is incorrect to describe it as having no comparison group. Moreover, the statement that the decrease in the rate of suicide attempts could represent regression to the mean needs clarification because there is no evidence that the mean rate of suicide attempts was higher than normal in the period before the subjects started taking clozapine.
Dr. Sernyak et al. also incorrectly characterized the study by Walker et al. (3) as having no "control group of similar patients not exposed to clozapine" and as employing a comparison group of patients who had stopped taking the medication and who would have been expected to "have a poorer clinical outcome" (1, p. 931). The comparison group in the study by Walker et al. (3) comprised patients who had recently begun taking clozapine, a clear indication of similarity with those who continued to take clozapine. There was no evidence to support the authors' conclusion that the patients who stopped taking clozapine were at greater risk for suicide. The standardized mortality rate of the comparison group (13.9) was well within the expected limits for patients with schizophrenia. The standardized mortality rate for the patients treated with clozapine was 2.27, which falls well outside the confidence interval of that for patients with schizophrenia, which has been reported to range from 9 to 20 in most studies.
Next, Dr. Sernyak et al. dismissed the data from Reid et al. (4) , which showed that the rate of suicide in clozapine-treated patients in the Texas Department of Mental Health and Mental Retardation was 12.7 out of 100,000 compared to 60-63 out of 100,000 of those not treated with clozapine, with the argument that no data were presented for basic demographic factors, such as age, gender, and race. There was no evidence that these differed in the two groups. The authors also failed to include a study by Munro et al. (5) , who reported that the standardized mortality rate in the entire Clozaril National Registry in Great Britain was 4.98, compared with a standardized mortality rate of 20 from other published studies of the general schizophrenia patient group. Both Meltzer and Okayli (2) and Reid et al. (4) reported similar data from the U.S. Clozaril National Registry from two different time periods. It is remarkable that all six of these studies showed a 75%-86% decrease in the rates of suicide attempts or completions after clozapine treatment. It is noteworthy that Dr. Sernyak et al. found a nearly significant effect of clozapine in reducing the rate of suicide in those who took clozapine for part, let alone, all of the period that they were at risk.
TO THE EDITOR: Dr. Sernyak et al. claimed that their results failed to support the hypothesis that clozapine treatment is associated with significantly fewer deaths due to suicide. The effect of clozapine on all causes of mortality, including suicide, was compared in a study with a group chosen by the use of "propensity scaling," a potentially problematic method that has severe limitations in this instance. It is a matter of concern that the variables available for subject matching did not include the four most important characteristics necessary for matching for suicide risk, i.e., the number, timing, and lethality of prior suicide attempts and the severity of depression at index admission. None of the variables used to create the comparison group, with the exception of substance abuse, is relevant to suicidality. This makes it difficult to be confident that the two groups had equivalent risks for suicide.
Dr. Sernyak et al. used data from a study by a colleague and me to conclude that treatment resistance is the most relevant factor in the matching process even though our finding was that there was no difference in the rate of suicidality between treatment-resistant and nonresistant patients. Furthermore, because the Department of Veterans Affairs (VA) policy of minimizing the use of clozapine led to clozapine use in 1% versus 6%-8% of non-VA patients with schizophrenia, the clozapine-treated patients in this study may not be representative of general users of clozapine in four previous studies Walker et al., 1997; Reid et al., 1998; and Munro et al., 1999) 
Dr. Talvik and Colleagues Reply
TO THE EDITOR: Drs. Pilowsky and Ell claim that clozapine treatment induces regionally selective occupancy of D 2 receptors in vivo. In our study we did not find support for regional selectivity. We agree with Drs. Pilowsky and Ell that this issue needs to be clarified.
Using the high-affinity PET radioligand [ 11 C]FLB 457, a close analog of the SPECT ligand [ 123 I]epidepride, we were initially puzzled by images that gave the impression of higher occupancy in extrastriatal regions. This unexpected observation was made for patients treated with clozapine and patients treated with low doses of haloperidol and seemed to be confirmed when ratio analyses were applied for the calculation of D 2 occupancy. However, this finding was not confirmed when we used [ 11 C]raclopride for striatal binding. We recently conducted a study that suggests methods limitations as a possible reason for the discrepant results (1) .
When ratio approaches are used to obtain reliable estimates for binding potential, the radioactivity must reach equilibrium during the acquisition time. The problem is that the time to reach equilibrium is highly dependent on the density of D 2 receptors, which varies about 100-fold in the human brain. A consequence is that regions with low receptor density (i.e., the temporal cortex) will reach equilibrium long before regions with high receptor density (i.e., the striatum). As shown in simulations based on experimental data, the endtime method, a ratio method used in SPECT, overestimates the binding potential if the time to equilibrium is within the time of data acquisition but underestimates the binding potential if the time to equilibrium falls beyond the acquisition time (1) . In SPECT studies using this method, low striatal and high extrastriatal binding potential have been reported (2, 3) . In the reports of the PET studies referred to in the letter, the methods were not reported in detail, which makes it difficult to appraise the results (Meltzer et al., 1999; Xiberas et al., 1999) . It cannot be discounted that these results were also influenced by the methods limitations of applying a ratio analysis on striatal binding at pre-equilibrium conditions.
